Academy of Medical Sciences of I.R. Iran Archives of Iranian Medicine 1029-2977 25 1 2022 01 01 Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD Medications 17 25 10.34172/aim.2022.04 EN Ali Reza Sima https://orcid.org/0000-0002-1397-4846 Bahar Saberzadeh-Ardestani Homayoon Vahedi Hafez Fakheri Fariborz Mansour-Ghanaei Iradj Maleki Siavosh Nasseri-Moghaddam Hasan Vosoghinia Mohammad Reza Ghadir Ahmad Hormati Amir Kasaeian Amir Reza Radmard Bardia Khosravi Masoud Malekzadeh Sudabeh Alatab Anahita Sadeghi Nayyereh Aminisani Hossein Poustchi Elnaz Gonoudi Amir Anushiravani Maryam Rayatpisheh Jean-Frederic Colombel Ryan C. Ungaro https://orcid.org/0000-0001-8687-3758 Reza Malekzadeh https://orcid.org/0000-0003-1043-3814 Journal Article 10.34172/aim.2022.04 2021 06 02 2021 10 04 Background: Most data on the effect of inflammatory bowel disease (IBD) and its treatments on coronavirus disease 2019 (COVID-19) outcomes have not had non-IBD comparators. Hence, we aimed to describe COVID-19 outcomes in IBD compared to non-IBD patients. Methods: We conducted a prospective cohort study of registered IBD patients with confirmed COVID-19 from six provinces in Iran from February to April 2020. Proven COVID-19 patients were followed up at four weeks and the frequency of outcomes was assessed. Multivariable logistic regression was used to assess associations between demographics, clinical characteristics and COVID-19 outcomes. Results: Overall, 2159 IBD patients and 4721 household members were enrolled, with 84 (3.9%) and 49 (1.1%) participants having confirmed COVID-19, respectively. Household spread of COVID-19 was not common in this cohort (1.2%). While hospitalization was significantly more frequent in IBD patients compared with non-IBD household members (27.1% vs. 6.0%, P=0.002), there was no significant difference in the frequency of severe cases. Age and presence of IBD were positively associated with hospitalization in IBD compared with non-IBD household members (OR: 1.06, 95% CI: 1.03-1.10; OR: 5.7, 95% CI: 2.02– 16.07, respectively). Age, presence of new gastrointestinal symptoms, and 5-aminosalicylic acid (5-ASA) use were associated with higher hospitalization rate in IBD patients (OR: 1.13, 95% CI: 1.05–1.23; OR: 6.49, 95% CI: 1.87–22.54; OR: 6.22, 95% CI: 1.90–20.36, respectively). Anti-tumor necrosis factor (TNF) was not associated with more severe outcomes. Conclusion: Age, presence of new gastrointestinal symptoms and use of 5-ASA were associated with increased hospitalization rate among IBD patients, while anti-TNF therapy had no statistical association.